Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – April 2011

Pages: 72 Published: March 15, 2011 Report Code: GDPH0216MD

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals April 2011” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in March 2011. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry. Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

Analysis of the market trends for the pharmaceutical industry in the global arena.

Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

Analysis of partnership and licensing deals based on clinical stage of development of products.

Summary of the pharmaceutical deals globally in the last six months.

Information on the top deals happened in the pharmaceutical industry.

Geographies covered include North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to Buy

Enhance your decision making capability in a more rapid and time sensitive manner.

Find out the major deal performing segments for investments in your industry.

Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

Identify companies that are aggressively looking to raise capital in the market

Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

Identify growth segments and opportunities in each region within the industry.

Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 6

1.2 List of Figures 8

2 Pharmaceuticals & Healthcare, Global, Deal Summary, 11

2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, March 2011 11

2.2 Pharmaceuticals & Healthcare, Global, Top Deals, March 2011 12

2.2.1 Sanofi Completes Public Offering Of Notes For $7 Billion 12

2.2.2 Cephalon Receives Proposal For Acquisition By Valeant Pharmaceuticals 12

2.2.3 Terumo To Acquire CaridianBCT From Gambro 13

2.2.4 Valeant Pharmaceuticals International Completes Private Placement Of Notes For $1.5 Billion 13

2.2.5 Quest Diagnostics Announces Public Offering Of Senior Notes For $1.25 Billion 13

2.3 Pharmaceuticals and Healthcare, Global, by Type, Number of Deals and Deal Values, March 2011 14

3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 15

3.1 Pharmaceuticals and Healthcare, Global, M&A, March 2011 15

3.1.1 Top M&A Deals in March 2011 16

3.1.2 Pharmaceuticals and Healthcare, Global M&A Deals by Therapy Area, October 2010 – March 2011 17

3.2 Pharmaceuticals and Healthcare, Global, Equity Offering Deals, March 2011 18

3.2.1 Top Equity Offering Deals in March 2011 19

3.2.2 Pharmaceuticals and Healthcare, Global, Equity Offering Deals by Therapy Area, October 2010 – March 2011 20

3.3 Pharmaceuticals and Healthcare, Global, Debt Offering Deals, March 2011 21

3.3.1 Top Debt Offering Deals in March 2011 22

3.3.2 Pharmaceuticals and Healthcare, Global, Debt Offering Deals, by Therapy Area, October 2010 – March 2011 23

3.4 Pharmaceuticals and Healthcare, Global, Private Equity and Venture Capital Deals, March 2011 24

3.4.1 Top PE/VC Deals in March 2011 25

3.4.2 Pharmaceuticals and Healthcare, Global, PE/VC by Therapy Area, March 2011 26

3.4.3 Pharmaceuticals and Healthcare, Global, Venture Capital Deals by Stage of Financing, March 2011 27

3.4.4 Pharmaceuticals and Healthcare, Global, Top Venture Financing Firms, October 2010 – March 2011 28

3.4.5 Pharmaceuticals and Healthcare, Global, Top VC Backed Companies, October 2010 – March 2011 29

4 Pharmaceuticals and Healthcare, Global, Partnership Deals, March 2011 30

4.1 Pharmaceuticals and Healthcare, Global, Partnership Deals, March 2011 30

4.2 Pharmaceuticals and Healthcare, Global, Partnership Deals by Therapy Area, October 2010 – March 2011 31

4.3 Pharmaceuticals and Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), March 2011 32

4.3.1 Pharmaceuticals and Healthcare, Global, Top Partnership Deals by Payment Mode, March 2011 33

4.4 Pharmaceuticals and Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), October 2010 – March 2011 34

4.5 Pharmaceuticals and Healthcare, Global, Partnership Deals by Phase, Number Of Deals and Deal Values (US$ m), October 2010 – March 2011 35

4.6 Pharmaceuticals and Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), October 2010 – March 2011 36

5 Pharmaceuticals and Healthcare, Global, Licensing Agreements, March 2011 37

5.1 Pharmaceuticals and Healthcare, Global, Licensing Agreements, March 2011 37

5.2 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), March 2011 38

5.2.1 Pharmaceuticals and Healthcare, Global, Top Licensing Agreements by Deal Value, March 2011 39

5.2.2 Pharmaceuticals and Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, March 2011 39

5.2.3 Pharmaceuticals and Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, March 2011 40

5.3 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal values (US$ m), October 2010 – March 2011 41

5.4 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), October 2010 – March 2011 42

5.5 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), October 2010 – March 2011 43

5.6 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), October 2010 – March 2011 44

6 Deal Summary by Therapy Area 45

6.1 Pharmaceuticals and Healthcare, Global, Oncology Deals, March 2011 45

6.1.1 Oncology – Deals of the Month 46

6.2 Pharmaceuticals and Healthcare, Global, Central Nervous System Deals, March 2011 47

6.2.1 Central Nervous System – Deals of the Month 48

6.3 Pharmaceuticals and Healthcare, Global, Immunology Deals, March 2011 49

6.3.1 Immunology – Deals of the Month 50

6.4 Pharmaceuticals and Healthcare, Global, Infectious Disease Deals, March 2011 51

6.4.1 Infectious Diseases – Deals of the Month 52

6.5 Pharmaceuticals and Healthcare, Global, Metabolic Disorders, Deals, March 2011 53

6.5.1 Metabolic Disorders – Deals of the Month 54

6.6 Pharmaceuticals and Healthcare, Global, Cardiovascular Deals, March 2011 55

6.6.1 Cardiovascular – Deals of the Month 56

6.7 Pharmaceuticals and Healthcare, Global, Respiratory Deals, March 2011 57

6.7.1 Respiratory – Deals of the Month 58

7 Deal Summary by Geography 59

7.1 Pharmaceuticals and Healthcare, North America Deals, March 2011 59

7.1.1 North America – Deals of the Month 60

7.2 Pharmaceuticals and Healthcare, Europe, Deals, March 2011 61

7.2.1 Europe – Deals of the Month 62

7.3 Pharmaceuticals and Healthcare, Asia-Pacific, Regional Deals, March 2011 63

7.3.1 Asia-Pacific – Deals of the Month 64

7.4 Pharmaceuticals and Healthcare, Rest of the World, Deals, March 2011 65

7.4.1 Rest of the World – Deals of the Month 66

8 Pharmaceuticals and Healthcare, Top Advisors 67

8.1 Pharmaceuticals and Healthcare, Global, Top Financial Advisors, M&A, October 2010 – March 2011 67

8.2 Pharmaceuticals and Healthcare, Global, Top Financial Advisors, Equity Offerings, October 2010 – March 2011 69

9 Further Information 71

9.1 Methodology 71

9.2 About GlobalData 72

9.3 Contact Us 72

9.4 Disclosure information 72

9.5 Disclaimer 72

List of Tables

1.1 List of Tables

Table 1: Pharmaceuticals and Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), October 2010 – March 2011 12

Table 2: Pharmaceuticals and Healthcare, Global, Top Deals, March 2011 12

Table 3: Pharmaceut

List of Figures

1.2 List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), October 2010 – March 2011 11

Figure 2: Pharmaceuticals and Healthcare, Global, Number Of Deals (%) and Deal Values (%),March 2011 14

Figure 3: Pha

$1,000

Can be used by individual purchaser only

$3,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about our multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Testimonial

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods
Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.

Pharmaceuticals
New
Net Present Value Model: (borneol + edaravone)
$500 | November 2022
Pharmaceuticals
New
Net Present Value Model: (Aspirin + Dipyridamole) ER
$500 | November 2022